FDA Actions in 2024
Twenty major actions the U.S. Food and Drug Administration took in 2024 on foods and food packaging, supplements and edibles, cosmetics, medical tests and devices, and prescription and over-the-counter drugs. Each page reports the action from the primary documents — the FDA announcement, the Federal Register notice, the order or letter itself — with what it did, what it did not do, and where it stands as of October 2026.
FDA Actions in 2024 (20)
In date order, oldest first. The stars rate each action's legal weight: ★★★★★ a final action that changes what is sold or labelled nationwide; ★★★★ a proposed rule or order, or a final action of narrower reach; ★★★ a formal safety review or a final guidance; ★★ a request for information or a public meeting.
FDA Urges Retailers to Stop Selling Tianeptine, “Gas Station Heroin” (2024)
January 2024: the FDA asked gas stations and convenience stores nationwide to stop selling tianeptine, an unapproved drug sold as a supplement, after seizures and deaths.
Read the full action →PFAS Grease-Proofing Leaves U.S. Food Packaging (2024)
February 2024: the FDA announced PFAS grease-proofers are no longer sold for U.S. food packaging, then added a PFAS import alert and a seafood data request.
Read the full action →FDA Allows a Qualified Yogurt and Type 2 Diabetes Claim (2024)
March 2024: the FDA said it will not object to labels saying 2 cups of yogurt weekly may reduce type 2 diabetes risk, noting limited evidence.
Read the full action →FDA Clears the First Over-the-Counter Continuous Glucose Monitor (2024)
March 2024: the FDA cleared the first continuous glucose monitor sold without a prescription, for adults not on insulin, including people without diabetes.
Read the full action →FDA Lead Alerts on Ground Cinnamon (2024)
March–December 2024: after the applesauce-pouch lead poisonings, FDA testing found lead in discount ground cinnamon, prompting recall requests, warning letters and import alerts.
Read the full action →FDA Approves Semaglutide to Cut Heart Risk in Obesity (2024)
March 2024: the FDA approved a weight-loss semaglutide injection to reduce cardiovascular death, heart attack and stroke in adults with heart disease and excess weight.
Read the full action →FDA Approves Resmetirom, the First Drug for Fatty-Liver Scarring (2024)
March 2024: the FDA approved resmetirom, the first medicine for adults with NASH (now called MASH) and moderate to advanced liver scarring, under accelerated approval.
Read the full action →FDA Response to H5N1 Bird Flu in Dairy Cattle and Milk (2024)
April–December 2024: as H5N1 bird flu spread in dairy cows, FDA testing found no live virus in pasteurized retail dairy and warned states about raw milk.
Read the full action →FDA Rule Bringing Laboratory-Developed Tests Under Device Law (2024)
May 2024: the FDA ruled that tests designed and run inside one laboratory are medical devices, phasing in oversight; a court vacated the rule in 2025.
Read the full action →FDA Declines to Approve MDMA-Assisted Therapy for PTSD (2024)
August 2024: the FDA declined to approve MDMA (midomafetamine) for PTSD, citing unreliable safety data, unproven durability and possible bias, and asked for another trial.
Read the full action →FDA Finds Amanita Muscaria Unsafe in Food After Mushroom-Edible Illnesses (2024)
June–December 2024: after 180 illnesses linked to “mushroom” chocolates and gummies, the FDA ruled Amanita muscaria and its compounds unauthorized in conventional food.
Read the full action →FDA Approves Donanemab for Early Alzheimer's Disease (2024)
July 2024: the FDA approved donanemab, a monthly amyloid-clearing antibody infusion, for mild cognitive impairment or mild dementia due to Alzheimer's disease.
Read the full action →FDA Revokes Brominated Vegetable Oil (BVO) in Food (2024)
July 2024: the FDA revoked the last authorization for brominated vegetable oil in food after new studies found thyroid harm in animals; enforcement began August 2025.
Read the full action →FDA and FTC Warn Sellers of Copycat Delta-8 THC Snacks (2024)
July 2024: the FDA and FTC warned six more sellers of delta-8 THC edibles packaged like popular chips, cookies and candy that children could mistake.
Read the full action →FDA Approves the First Needle-Free Epinephrine for Anaphylaxis (2024)
August 2024: the FDA approved the first epinephrine nasal spray for emergency treatment of severe allergic reactions, the first option not given by injection.
Read the full action →FDA Approves a New-Mechanism Schizophrenia Drug (2024)
September 2024: the FDA approved xanomeline-trospium, the first schizophrenia drug that targets cholinergic receptors instead of dopamine receptors, a new approach in decades.
Read the full action →FDA Ends the Tirzepatide Shortage, Limiting Compounded Copies (2024)
October–December 2024: the FDA declared the tirzepatide injection shortage over, re-confirmed it after a court remand, and set wind-down dates for compounded copies.
Read the full action →FDA Proposal to Remove Oral Phenylephrine as a Decongestant (2024)
November 2024: the FDA proposed removing oral phenylephrine from the over-the-counter cold medicine monograph, finding it does not work as a nasal decongestant.
Read the full action →FDA Final Rule Redefining “Healthy” on Food Labels (2024)
December 2024: the FDA redefined the “healthy” label claim around food groups plus limits on added sugar, sodium and saturated fat, replacing the 1994 definition.
Read the full action →FDA Proposal to Require Asbestos Testing of Talc Cosmetics (2024)
December 2024: the FDA proposed requiring every talc-containing cosmetic, batch by batch, to be tested for asbestos by two microscopy methods; withdrawn in November 2025.
Read the full action →